CRMD vs. KYMR, MOR, HCM, RARE, ALVO, AMRX, MIRM, CPRX, ARWR, and IBRX
Should you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include Kymera Therapeutics (KYMR), MorphoSys (MOR), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), Alvotech (ALVO), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Arrowhead Pharmaceuticals (ARWR), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.
CorMedix vs. Its Competitors
Kymera Therapeutics (NASDAQ:KYMR) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
In the previous week, Kymera Therapeutics had 3 more articles in the media than CorMedix. MarketBeat recorded 5 mentions for Kymera Therapeutics and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.55 beat Kymera Therapeutics' score of 0.76 indicating that CorMedix is being referred to more favorably in the news media.
CorMedix has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.
Kymera Therapeutics currently has a consensus price target of $59.11, indicating a potential upside of 28.92%. CorMedix has a consensus price target of $17.14, indicating a potential upside of 49.07%. Given CorMedix's higher possible upside, analysts clearly believe CorMedix is more favorable than Kymera Therapeutics.
CorMedix has a net margin of 20.81% compared to Kymera Therapeutics' net margin of -409.07%. CorMedix's return on equity of 22.57% beat Kymera Therapeutics' return on equity.
34.2% of CorMedix shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 5.3% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Kymera Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500.
Summary
CorMedix beats Kymera Therapeutics on 9 of the 17 factors compared between the two stocks.
Get CorMedix News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CorMedix Competitors List
Related Companies and Tools
This page (NASDAQ:CRMD) was last updated on 7/24/2025 by MarketBeat.com Staff
Free CRMD Stock Alerts